Shingles (Acute Herpes Zoster)
No controlled study of leech therapy for acute shingles exists; antiviral treatment started early is standard care, and leeches must never be placed on or near the rash.
Patient Summary
- Is this FDA-cleared for this use?
- No. The FDA cleared medicinal leeches in 2004 only for venous congestion in microsurgical reconstruction (K040187). Use for shingles is not FDA-evaluated and is not supported by any controlled study.
- What evidence exists?
- Shingles is treated with an antiviral medicine, ideally started within 72 hours after the rash appears, together with pain relief. This is standard care and it comes first. No controlled study has tested leech therapy for shingles. The few published reports each describe a single patient who received leeches together with other treatments, so they cannot show that leeches helped. A 2007 leech therapy handbook, one of the two main reference books of this society, says leech therapy has established itself as a viable alternative for shingles but states that scientific study data are not available; the same handbook advises against leech therapy during acute infections and against use on inflamed or ulcerated skin. ASH does not treat that passage as evidence that leeches work or are safe during the rash. Leeches must never be placed on or near shingles blisters or crusts. The recombinant zoster vaccine greatly lowered the risk of shingles in large trials.
- Main risks
- Delay of antiviral treatment, which works best when started within 72 hours of the rash
- Weakness and impaired wound healing when leech therapy is used during an acute infection (reported in the 2007 handbook)
- Local skin infection of the bite sites or, rarely, Aeromonas infection from leech gut bacteria
- Spread of the shingles virus: fluid from open blisters can infect people who have never had chickenpox
- Bleeding and oozing from each bite site for several hours, sometimes up to 24 hours
- Itching, redness, and irritation at the bite sites lasting days to weeks
- Allergic reaction to leech saliva (uncommon)
- Scarring, color changes, or keloids at bite sites
- Anemia if blood loss is repeated
- Who should not consider this
- Anyone with shingles blisters, crusts, or broken skin: leeches must never be placed on or near the rash
- Anyone who has not yet been examined by a doctor for the rash or has not started antiviral treatment
- People with a rash near the eye, on the forehead or the tip of the nose, or near the ear, or with facial weakness, hearing loss, or dizziness
- People with a weakened immune system, for example during chemotherapy or with HIV infection
- People with fever or another acute infection
- Patients taking blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, or heparin
- Patients with hemophilia or other inherited bleeding disorders
- Patients with anemia
- People with diabetes or another condition that slows wound healing
- Pregnant patients (leech therapy is not done during pregnancy)
- What to ask your clinician
- Is this shingles, and should I start an antiviral medicine now? (It works best within 72 hours of the rash.)
- Is my rash near my eye, nose, or ear, and do I need an eye or ear specialist today?
- Am I at higher risk of complications (older age, weakened immune system, diabetes)?
- What can I do for the pain, and what should I do if the pain lasts after the rash heals?
- How do I protect other people while my blisters are open, and when am I no longer contagious?
- Am I eligible for the recombinant shingles vaccine, and when should I get it?
- What evidence exists for leech therapy in shingles, and why would it be added to standard care? (No controlled study was found for this page.)
- When to seek urgent care
- A new painful rash or blisters on one side of the body: see a doctor as soon as possible, ideally within 72 hours, to start antiviral treatment
- Rash, pain, or redness on the forehead, around the eye, or on the tip of the nose, eye pain, or blurred vision (possible shingles of the eye, which can threaten sight: see a doctor or eye specialist at once)
- Rash in or around the ear, hearing loss, dizziness, or weakness of one side of the face (possible Ramsay Hunt syndrome)
- Shingles with a weakened immune system, a rash spreading widely over the body, or fever
- Confusion, severe headache, or trouble breathing
- Spreading redness, warmth, pus, red streaks, or increasing pain around blisters or bite sites
- Bleeding from a bite site lasting more than 24 hours or soaking through dressings
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for shingles - it is not.
- It does not mean leech therapy helps shingles - it rests on three single-patient reports that combined leeches with other treatments, and the one book passage states that no scientific study data are available.
- It does not mean leech therapy replaces antiviral medicine started early, pain care, or vaccination. No controlled study shows that leeches act against the virus or prevent lasting nerve pain.
- It does not mean leeches may be placed on or near blisters, crusts, or broken skin - they must never be.
- It does not mean the handbook passage on shingles is a recommendation to use leeches during the rash: the same handbook advises against leech therapy in acute infectious disease.
Safety cross-references
Clinical Profile
- Category
- Dermatological
- ICD-10
- B02.9, B02.8, B02.7, B02.30
- Safety tier
- High
Evidence Summary
Shingles (herpes zoster) is a painful blistering rash caused by reactivation of the varicella-zoster virus, usually on one side of the body; the rash typically heals in 2 to 4 weeks (CDC). Standard care is an oral antiviral medicine (acyclovir, valacyclovir or famciclovir), ideally started within 72 hours of the rash appearing, together with pain control (Dworkin 2007; Saguil 2017; CDC). These drugs speed resolution of the lesions, reduce new lesions and viral shedding, and decrease the severity of acute pain (CDC); a Cochrane review (Chen 2014) found that oral aciclovir did not significantly reduce the incidence of postherpetic neuralgia. Complications include postherpetic neuralgia, hearing or vision loss, encephalitis and pneumonia, and older adults and people with a weakened immune system are at high risk of them (CDC). Shingles involving the eye needs urgent assessment because early diagnosis and treatment aim to prevent progressive corneal involvement and potential vision loss (CDC), and shingles near the ear with facial weakness (Ramsay Hunt syndrome) often causes more severe paralysis at onset and a lower chance of full recovery than Bell's palsy (Sweeney and Gilden 2001). Vaccination is the main prevention: in placebo-controlled trials the recombinant zoster vaccine lowered the risk of shingles by 97.2% in adults 50 and older (ZOE-50, 15,411 evaluable participants) and by 89.8% in adults 70 and older (ZOE-70, 13,900 evaluable participants). No randomized or other controlled study of leech therapy for acute shingles was identified in PubMed, Europe PMC or ClinicalTrials.gov (searched 2026-11-12). The published human reports are three single-patient case reports (Nakanekar 2020; Itankar 2025; Schwickert 2006), each combining leeches with other treatments and without a comparison group, so they cannot show that leeches caused any improvement; one of them (Schwickert 2006) concerned recurrent shingles with a rash and nerve pain lasting 3 months, not the acute rash. Of the two reference books of this society, Baskova and Isakhanyan (2004) does not mention shingles; Michalsen, Roth and Dobos (2007, p. 82) say that leech therapy has established itself as a viable alternative for shingles but state that scientific study data are not available. The same handbook advises against leech therapy during the acute stages of infectious disease because of weakness and impaired wound healing (p. 104), and against placing leeches on skin with marked dermatitis or ulceration (p. 68). ASH does not treat the shingles passage as evidence that leech therapy works or is safe during the rash. Leech therapy is not a substitute for early antiviral treatment, pain care or vaccination, and leeches must never be placed on or near blisters, crusts or broken skin.
What the books describe
Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.
- Baskova and Isakhanyan do not write about herpes zoster (shingles)[B1].
- Flecken and Michalsen write that hirudotherapy has established itself in practice as a viable alternative for herpes zoster (shingles), although scientific study data are not available[B3].
- In the chapter on contraindications the same authors write that, according to experience, hirudotherapy during the acute stages of infectious diseases may lead to subjective weakness and impaired wound healing, and that, according to the broader concepts of naturopathic medicine and humoral pathology, any treatment that extracts blood from a patient with an infectious disease is generally considered unhelpful and is not recommended[B3].
- Baskova and Isakhanyan advise refraining from the use of leeches at a high body temperature[B1].
- Herpes zoster is not named in the chapter on contraindications, so it is not clear from the text whether the authors count it among acute infectious diseases in this sense; they do not connect their statement about herpes zoster (p. 82) with the warning from chapter 8[B3].
- Both books list hemophilia and concurrent use of anticoagulants (medicines that reduce blood clotting) among the contraindications, and Flecken and Michalsen add that hirudotherapy should never be performed in patients with severe, unstable diseases of the organs or marked suppression of the immune system (chemotherapy)[B1][B3].
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Key Trials
- Nakanekar A et al. (2020), n=1 · J Ayurveda Integr Med · PMID 32798195 · ASH analysis →
- Itankar PB et al. (2025), n=1 · J Pharm Bioallied Sci · PMID 41846760 · ASH analysis →
- Schwickert M, Saha J (2006), n=1 · Forsch Komplementmed [de] · PMID 16868364
- Nakanekar A et al. 20201
- Itankar PB et al. 20251
- Schwickert M, Saha J 20061
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Shingles with blisters, crusts or broken skin: leeches must never be placed on or near the affected skin
- Shingles that has not yet been seen by a doctor, or antiviral treatment not yet started
- Rash or pain near the eye, on the forehead or the tip of the nose, or near the ear, or with facial weakness, hearing loss or dizziness, until examined by a doctor
- Shingles in a person with a weakened immune system, or with a widespread rash or signs of complications
- Diabetes or another condition with impaired wound healing
Related Conditions
Post-Herpetic Neuralgia (Investigational Adjunct)
Investigational adjunct for chronic post-herpetic neuralgia; gabapentinoids, tricyclics, and topical lidocaine/capsaicin remain evidence-based; herpes zoster vaccine prevents new cases.
Ramsay Hunt Syndrome (Investigational Adjunct, Convalescent Phase)
Investigational adjunct for convalescent-phase Ramsay Hunt syndrome residual facial weakness; antiviral plus corticosteroid started within 72 hours of onset remains evidence-based.
Bell's Palsy (Acute Idiopathic Facial Paralysis)
Investigational adjunct in acute idiopathic facial nerve palsy; no controlled trial identified, only uncontrolled series and single-case reports.
Livedo Reticularis
Investigational use for primary livedo reticularis; no clinical study was identified. Secondary causes (lupus, APLAS) require rheumatology referral.
References
- [B1]
Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]
Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.
- [B3]
Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy
ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.
The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.